Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Abstract 1628: Tumor cell specific inhibition of oncogenic Wnt signaling

View through CrossRef
Abstract Aberrant activation of the Wnt/β-catenin pathway is one of the most frequent signaling abnormalities known in human cancer and contributes to both tumor initiation and tumor maintenance. In normal tissues, however, the Wnt/β-catenin pathway plays widespread and important roles in the regulation of stem cell behavior, differentiation, and homeostasis. Consequently, a challenge in developing strategies for antagonizing Wnt signaling in cancer will be to minimize harmful side-effects on normal tissues. In many human cancers the canonical Wnt pathway is activated by single base missense mutations in β-catenin located near N-terminal phosphorylation sites that control the protein's stability. These mutant forms of β-catenin represent targets that are unique to cancer cells. We have screened RNAi reagents designed specifically to target individual mutant β-catenin sequences found in cancer cells while having minimal impact on wild-type β-catenin. We have used colorectal and hepatoma cell lines with defined β-catenin mutations for initial evaluation of the efficacy and specificity of knock-down, in conjunction with signaling assays based on nuclear accumulation of β-catenin and TCF-responsive reporter assays. We find that mutation-specific siRNA or shRNA reagents can be identified that substantially reduce β-catenin levels in cancer cells bearing the respective mutation, but have little or no effect on cells that are wild-type for β-catenin or which carry a different mutation. We also observe mutation-specific inhibitory effects on cell growth. These results provide encouragement for developing this strategy as a means of silencing oncogenic mutations in cancer while causing only minimal collateral damage to normal tissues. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1628.
American Association for Cancer Research (AACR)
Title: Abstract 1628: Tumor cell specific inhibition of oncogenic Wnt signaling
Description:
Abstract Aberrant activation of the Wnt/β-catenin pathway is one of the most frequent signaling abnormalities known in human cancer and contributes to both tumor initiation and tumor maintenance.
In normal tissues, however, the Wnt/β-catenin pathway plays widespread and important roles in the regulation of stem cell behavior, differentiation, and homeostasis.
Consequently, a challenge in developing strategies for antagonizing Wnt signaling in cancer will be to minimize harmful side-effects on normal tissues.
In many human cancers the canonical Wnt pathway is activated by single base missense mutations in β-catenin located near N-terminal phosphorylation sites that control the protein's stability.
These mutant forms of β-catenin represent targets that are unique to cancer cells.
We have screened RNAi reagents designed specifically to target individual mutant β-catenin sequences found in cancer cells while having minimal impact on wild-type β-catenin.
We have used colorectal and hepatoma cell lines with defined β-catenin mutations for initial evaluation of the efficacy and specificity of knock-down, in conjunction with signaling assays based on nuclear accumulation of β-catenin and TCF-responsive reporter assays.
We find that mutation-specific siRNA or shRNA reagents can be identified that substantially reduce β-catenin levels in cancer cells bearing the respective mutation, but have little or no effect on cells that are wild-type for β-catenin or which carry a different mutation.
We also observe mutation-specific inhibitory effects on cell growth.
These results provide encouragement for developing this strategy as a means of silencing oncogenic mutations in cancer while causing only minimal collateral damage to normal tissues.
Citation Format: {Authors}.
{Abstract title} [abstract].
In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC.
Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1628.

Related Results

WNT Receptor Requirements for Dishevelled Phosphorylation
WNT Receptor Requirements for Dishevelled Phosphorylation
The Dishevelled (DVL) protein is a key component of WNT signaling that relays signals from receptors to downstream effectors. It has been shown that following WNT ligand binding to...
Abstract 1584: Wnt/beta-catenin and Foxa2 axis activates AR signaling in castration resistant prostate cancer
Abstract 1584: Wnt/beta-catenin and Foxa2 axis activates AR signaling in castration resistant prostate cancer
Abstract Background: Prostate cancer (PCa) is the leading cancer among men in the world. Androgen deprivation therapy is a common treatment to cease prostate growth....
WNT Signaling Pathway and Stem Cell Signaling Network
WNT Signaling Pathway and Stem Cell Signaling Network
Abstract WNT signals are transduced to the canonical pathway for cell fate determination, and to the noncanonical pathway for control of cell movement and tissue pol...
WNT Signaling Influences Neurological Function and Psychiatric Disorders Through Regulating Glia Phenotypes and Neuron Plasticity
WNT Signaling Influences Neurological Function and Psychiatric Disorders Through Regulating Glia Phenotypes and Neuron Plasticity
Abstract Background: As an important signaling pathway during embryonic development, WNT/β-catenin signaling regulates cell proliferation and differentiation. However, the ...
Role of Wnt Signaling in Colon Cancer Cell Metabolism
Role of Wnt Signaling in Colon Cancer Cell Metabolism
Over eighty percent of colon cancers derive from mutations that overactivate the Wnt pathway and cause cell transformation. These mutations stabilize β‐catenin protein, leading to ...
Giant Sacrococcygeal Teratoma in Infant: Systematic Review
Giant Sacrococcygeal Teratoma in Infant: Systematic Review
Abstract Introduction Sacrococcygeal teratoma (SCT) is a rare embryonal tumor that occurs in the sacrococcygeal region, with an incidence of about 1 in 35,000 to 40,000 live births...
Abstract 1713: Macrophage-induced bystander effect activates Wnt/β-catenin signaling and induces cellular dedifferentiation
Abstract 1713: Macrophage-induced bystander effect activates Wnt/β-catenin signaling and induces cellular dedifferentiation
Abstract Cancer stem cells (CSCs) in colorectal cancer (CRC) help maintain tumor heterogeneity, promote tumor growth, invasion, and metastasis, and produce resistanc...
Tumor specificity of WNT ligands and receptors reveals universal squamous cell carcinoma oncogenes
Tumor specificity of WNT ligands and receptors reveals universal squamous cell carcinoma oncogenes
Abstract Background The WNT signal pathway has myriad family members, which are broadly involved in embryonic development and human cancer. Over-act...

Back to Top